IGEA Research Corporation is a new biomedical company that opened in 2015 in Miami, Florida, a strategic location for international collaborations and development. After several years investigating the metabolic processes that impact Alzheimer's Disease, IGEA Research Corporation developed the ALZ-1 Test, a new tool to measure for dysfunction of copper metabolism that can be catastrophic in the evolution of a patient's cognitive state and medical condition. IGEA Research Corporation has developed and patented an easy and reliable test by which Non Cp-Copper, considered to be one of the main risk factors for Alzheimer's disease, can be measured. This accurate, reliable test is now available as the ALZ-1 Test.